SNT-3012 / Sonata Therap, Champalimaud Foundation - LARVOL DELTA

Harnessing viral-mimicry and synthetic cell death, SNT-3012 induces protective immunity across genetically diverse tumor landscapes: a story of transitioning a preclinical asset to human validation (SITC 2024) - "This approach's therapeutic potential presents an exciting avenue for future cancer treatment investigations.Download figure Open in new tab Download powerpoint Abstract 1327 Figure 1 Antitumoral immunity induced by SNT-3012. SNT-3012 induces direct cytotoxicity, robust inflammatory activation which leads to the generation of profound antitumoral immunity across a variety of murine tumor models"

IO biomarker • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CXCL10 • IL12A

Harnessing viral-mimicry and synthetic cell death, SNT-3012 induces protective immunity across genetically diverse tumor landscapes: a story of transitioning a preclinical asset to human validation (SITC 2024) - "This approach's therapeutic potential presents an exciting avenue for future cancer treatment investigations.Download figure Open in new tab Download powerpoint Abstract 1327 Figure 1 Antitumoral immunity induced by SNT-3012. SNT-3012 induces direct cytotoxicity, robust inflammatory activation which leads to the generation of profound antitumoral immunity across a variety of murine tumor models"

IO biomarker • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CXCL10 • IL12A

Sonata Therapeutics and the Champalimaud Foundation Announce Research Collaboration for SNT-3012 in Pancreatic and Colorectal Cancers (PRNewswire) - "Sonata Therapeutics...and the Champalimaud Foundation...announced a research collaboration for the development of Sonata's novel Network Medicine, SNT-3012. The partnership will drive the continued research and development of SNT-3012 for the treatment of pancreatic and colorectal cancers. The collaboration combines Sonata's foundational understanding of Network Medicines with the Champalimaud Foundation's patient-derived samples as well as scientific and clinical excellence to conduct proof-of-concept studies that will play a role in the clinical translation of SNT-3012."

Licensing / partnership • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor